Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal <scp>OVERCOME</scp> ( <scp>US</scp> ) study
This work expands the concept of migraine progression, exploring two alternative definitions that modify the potential range of MHD changes and take disability into account. This analysis identified never having used preventive medications for migraine and presence of depression as risk factors across all three definitions of progression. This work may more accurately identify persons with progression and at risk of migraine progression, setting the stage for trials of preventive intervention and ultimately more effective practice.
Authors
- Richard B. Lipton (ORCID: https://orcid.org/0000-0003-2652-2897)
- Anthony J. Zagar (ORCID: https://orcid.org/0000-0002-8353-6665)
- Gilwan Kim (ORCID: https://orcid.org/0000-0003-1991-6644)
- Sait Ashina (ORCID: https://orcid.org/0000-0003-3973-6640)
- E. Jolanda Muenzel (ORCID: https://orcid.org/0009-0000-7929-3704)
- Robert A. Nicholson (ORCID: https://orcid.org/0000-0002-2725-9739)
- Robert E. Shapiro (ORCID: https://orcid.org/0000-0002-7401-0514)
- Dawn C. Buse
- Ali Sheikhi Mehrabadi
Institutions
- University of Vermont (US)
- Albert Einstein College of Medicine (US)
- Beth Israel Deaconess Medical Center (US)
- Montefiore Medical Center (US)
- Harvard University (US)
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1111/head.14925
- Citations
- 10
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 14.71
Funders
- Eli Lilly and Company